ARS Pharmaceuticals launched the Get neffy on Us program on Nov 4, 2025, offering eligible patients a free virtual visit and a $0 co‑pay for its needle‑free epinephrine nasal spray, neffy.
The program removes two key adoption barriers: the cost of the product and the requirement for an in‑person prescription. By eliminating these obstacles, ARS aims to broaden its patient base and accelerate prescription uptake, a critical step toward securing unrestricted payer coverage.
The initiative is part of ARS’s broader commercial strategy, which includes a direct sales force and a co‑promotion partnership with ALK that began at the end of May 2025. The program also complements the company’s neffyInSchools initiative, which supplies neffy to schools. By launching ahead of the peak allergy season, ARS seeks to drive market penetration and support long‑term revenue growth.
ARS has already achieved 93% commercial coverage of neffy by August 2025, up from 80% in summer 2025, and is targeting 100% coverage by the end of the year. The company estimates that 40 million U.S. residents live with severe allergies, and consumer surveys show that more than 70% of patients are open to virtual prescribing options. The Get neffy on Us program is designed to address these market dynamics and to overcome the cost and prescription barriers that have limited broader adoption of needle‑free epinephrine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.